Research Article: Hsa_circ_ Overexpression Suppresses the Progression of Triple-Negative Breast Cancer via Regulating miR--p-FOXO Axis
Abstract:
Breast cancer is the most common cancer, with more than . million new cases and approximately , deaths worldwide. Breast cancer is classified into luminal, HER-amplified, and triple-negative breast cancer (TNBC). Luminal breast cancer, the most common subtype, has the best prognosis and benefits from targeted endocrine therapy due to hormone receptor expression as well as HER-amplified breast cancer benefits from anti-HER therapy. However, TNBC is a biologically and clinically heterogeneous disease that differs from other subtypes, TNBC develops metastases earlier after diagnosis, with higher brain, liver, and lung metastasis rates, and relatively poor outcomes and prognosis. Endocrine therapy, molecular-targeted therapy, and chemotherapy, which are effective for other subtypes, are not effective for treating TNBC, and standardized treatment protocols for TNBC are lacking. Three randomized clinical trials of combination treatment strategies using immunomodulators (monoclonal antibodies) and chemotherapeutic agents are underway., Therefore, developing new therapeutic regimens and targets for TNBC is urgently required.
Introduction:
Breast cancer is the most common cancer, with more than . million new cases and approximately , deaths worldwide. Breast cancer is classified into luminal, HER-amplified, and triple-negative breast cancer (TNBC). Luminal breast cancer, the most common subtype, has the best prognosis and benefits from targeted endocrine therapy due to hormone receptor expression as well as HER-amplified breast cancer benefits from anti-HER therapy. However, TNBC is a biologically and clinically heterogeneous disease that differs…
Read more